Multiple Sclerosis Treatment: High-Efficacy First-Line Evidence and the Pipeline Ahead
An evidence synthesis on the shift toward high-efficacy first-line strategies in relapsing multiple sclerosis treatment, with a focused review of anti-CD20 therapies, BTK inhibitors, and the emerging DELIVER-MS comparative data.
One-Minute Takeaway on Multiple Sclerosis Treatment
One-Minute Takeaway
- Modern multiple sclerosis treatment is increasingly built around early high-efficacy disease-modifying therapy rather than stepwise escalation, supported by observational data and emerging randomised evidence.
- Anti-CD20 monoclonal antibodies — ocrelizumab and ofatumumab — have reset the efficacy benchmark, achieving annualised relapse-rate reductions of 46% and 50% versus active comparators in pivotal trials.
- The DELIVER-MS trial directly compares high-efficacy first-line therapy with traditional escalation; preliminary signals favour the high-efficacy arm on radiological outcomes.
- Brain-penetrant BTK inhibitors led by tolebrutinib showed mixed results, with HERCULES positive in non-relapsing secondary progressive disease but GEMINI failing in relapsing disease.
- Long-term safety surveillance for newer agents and equitable access remain unresolved gaps in real-world multiple sclerosis treatment.
Why Multiple Sclerosis Treatment Matters Now
Multiple sclerosis affects an estimated 2.9 million people worldwide, with incidence rising steadily over the past two decades. The therapeutic landscape has expanded from two injectable options in the 1990s to more than fifteen disease-modifying therapies spanning oral, infusion, and subcutaneous formulations.
This expansion has produced a fundamental shift in clinical thinking. The traditional escalation paradigm — beginning with moderate-efficacy injectables and intensifying only after breakthrough disease activity — has been increasingly challenged by data suggesting that early high-efficacy multiple sclerosis treatment may better preserve long-term neurological function.
Three forces converge to make this question urgent. First, anti-CD20 therapies have raised the efficacy ceiling. Second, the DELIVER-MS and TREAT-MS trials are generating direct randomised evidence on sequencing strategy. Third, BTK inhibitors aim to address progression independent of relapse activity — a domain where current multiple sclerosis treatment options have limited efficacy.
What Evidence Was Reviewed
This synthesis draws on eleven major trials and large observational cohorts published between 2006 and 2024. Studies were selected for direct relevance to first-line therapy choice, anti-CD20 monoclonal antibody efficacy, BTK inhibitor outcomes, and the high-efficacy versus escalation question. Sample sizes range from 234 to 4,469 participants.
| Study | Design | n | Comparison | Key Finding |
|---|---|---|---|---|
| OPERA I & II (Hauser 2017) | Phase 3 RCTs | 1,656 | Ocrelizumab vs IFN beta-1a | ARR reduced by 46% |
| ORATORIO (Montalban 2017) | Phase 3 RCT | 732 | Ocrelizumab vs placebo (PPMS) | 12-week CDP HR 0.76 |
| ASCLEPIOS I & II (Hauser 2020) | Phase 3 RCTs | 1,882 | Ofatumumab vs teriflunomide | ARR reduced by ~50% |
| AFFIRM (Polman 2006) | Phase 3 RCT | 942 | Natalizumab vs placebo | ARR reduced by 68% |
| CARE-MS I (Cohen 2012) | Phase 3 RCT | 581 | Alemtuzumab vs IFN (naive) | ARR reduced by 55% |
| CLARITY (Giovannoni 2010) | Phase 3 RCT | 1,326 | Cladribine vs placebo | ARR reduced by 58% |
| EXPAND (Kappos 2018) | Phase 3 RCT | 1,651 | Siponimod vs placebo (SPMS) | 3-month CDP reduced by 21% |
| Brown (JAMA 2019) | Observational cohort | 1,555 | Early high-efficacy vs escalation | 5-year EDSS HR 0.66 |
| He (JAMA Neurol 2020) | Observational cohort | 2,096 | Early intensive vs escalation | SPMS conversion HR 0.66 |
| HERCULES (Fox 2024) | Phase 3 RCT | 1,131 | Tolebrutinib vs placebo (nrSPMS) | 6-month CDP HR 0.69 |
| GEMINI 1 & 2 (Oh 2024) | Phase 3 RCTs | 2,200 | Tolebrutinib vs teriflunomide (RMS) | ARR primary endpoint not met |
Key Findings on Multiple Sclerosis Treatment
Insight 1: Anti-CD20 Therapies Have Reset the Efficacy Benchmark
Ocrelizumab in the OPERA I and II trials reduced annualised relapse rate by 46% versus subcutaneous interferon beta-1a (0.16 vs 0.29 relapses per year). Ofatumumab in ASCLEPIOS I and II reduced relapse rate by approximately 50% versus oral teriflunomide. Both therapies also reduced 24-week confirmed disability progression.
These two anti-CD20 agents share a mechanism — selective B-cell depletion — but differ in administration: ocrelizumab is given as twice-yearly intravenous infusion, ofatumumab as monthly subcutaneous injection. The convergent efficacy across two large pivotal programmes positions B-cell depletion as a foundational strategy in modern multiple sclerosis treatment.
Insight 2: Observational Evidence Favours Early High-Efficacy Therapy
Two large international cohorts have addressed the sequencing question. The Brown 2019 JAMA analysis of 1,555 patients found that initial high-efficacy therapy was associated with a hazard ratio of 0.66 (95% CI 0.44–1.00) for sustained 5-year EDSS worsening compared with escalation strategies. The He 2020 JAMA Neurology cohort reported a similar HR of 0.66 (95% CI 0.50–0.86) for conversion to secondary progressive disease.
These findings are consistent in direction and effect size but limited by treatment-selection confounding. Patients started on high-efficacy multiple sclerosis treatment differ systematically from those on platform therapies. This is precisely the question randomised trials such as DELIVER-MS and TREAT-MS were designed to resolve.
Insight 3: DELIVER-MS Provides the First Randomised Sequencing Data
DELIVER-MS randomised patients with newly diagnosed relapsing multiple sclerosis to early high-efficacy therapy versus traditional escalation, with brain volume change as the primary outcome. Preliminary 24-month results presented at ECTRIMS suggest a numerical advantage for the high-efficacy arm on percentage brain volume change and new T2 lesion accrual.
The trial’s pragmatic design allows physician choice within each arm, increasing external validity but introducing within-arm heterogeneity. Definitive long-term disability outcomes await further follow-up. Together with TREAT-MS, DELIVER-MS represents the first generation of randomised evidence directly addressing the central strategic question in multiple sclerosis treatment.
Insight 4: Drug Class Differentiation Reflects Efficacy–Safety Tradeoffs
Pivotal trials enable indirect comparison across drug classes. Natalizumab in AFFIRM produced the largest relapse-rate reduction at 68%, but progressive multifocal leukoencephalopathy risk in JC virus-positive patients constrains its use. Alemtuzumab in CARE-MS I reduced relapse rate by 55% but carries autoimmune and vascular risks requiring intensive monitoring.
Cladribine produced a 58% reduction in CLARITY with a brief immune reconstitution profile and no continuous dosing. Anti-CD20 therapies sit in a comparable efficacy band with a generally favourable safety profile, though hypogammaglobulinaemia and infection risk emerge with prolonged exposure. Multiple sclerosis treatment selection therefore weighs efficacy against tolerability, monitoring burden, and long-term safety.
Insight 5: The BTK Inhibitor Class Has Delivered Mixed Signals
Tolebrutinib, a brain-penetrant BTK inhibitor, was tested across three phase 3 programmes. HERCULES in non-relapsing secondary progressive disease met its primary endpoint, reducing 6-month confirmed disability progression with a hazard ratio of 0.69 (95% CI 0.55–0.88) versus placebo — the first positive trial in this difficult population since siponimod in EXPAND.
In contrast, the GEMINI 1 and 2 trials in relapsing multiple sclerosis treatment failed to demonstrate superiority over teriflunomide on annualised relapse rate, although MRI and disability secondary endpoints showed favourable trends. Hepatic adverse events have prompted regulatory holds and risk-mitigation programmes. The class signal suggests BTK inhibition may target compartmentalised inflammation more than peripheral relapse biology.
Insight 6: Progressive Disease Remains the Hardest Therapeutic Frontier
Three trials anchor progressive disease evidence. ORATORIO showed ocrelizumab reduced 12-week confirmed disability progression by 24% in primary progressive multiple sclerosis. EXPAND showed siponimod reduced 3-month confirmed disability progression by 21% in active secondary progressive disease. HERCULES extends the evidence to non-relapsing secondary progressive disease.
Effect sizes in progressive disease are modest compared with the relapse-rate effects seen in relapsing populations. The persistent gap between relapse control and progression control in multiple sclerosis treatment underscores why neuroprotective and remyelinating strategies remain active research priorities.
The strategic question in modern multiple sclerosis treatment has shifted from which agent to use, to when to use the most effective agent — and observational data, supported by emerging randomised evidence, increasingly favour earlier deployment.
— Synthesis of OPERA, ASCLEPIOS, Brown 2019, He 2020, and DELIVER-MS preliminary data
Quality & Consistency of Evidence
The evidence base supporting modern multiple sclerosis treatment is among the most extensive in any neurological condition. Randomised trial methodology has been refined across two decades of regulatory development. Observational evidence draws on large international registries with prospective standardised data collection.
- Anti-CD20 efficacy in relapsing disease: highly concordant across OPERA I, OPERA II, ASCLEPIOS I, and ASCLEPIOS II — relapse-rate reductions of 46–50% versus active comparators with low between-trial heterogeneity.
- Natalizumab and alemtuzumab efficacy: robust placebo- and active-comparator trial data with consistent direction across populations.
- Early high-efficacy therapy benefit: consistent observational cohorts (Brown 2019, He 2020) but treatment-selection confounding limits causal inference; awaiting DELIVER-MS and TREAT-MS final disability outcomes.
- Progressive disease therapy: ORATORIO, EXPAND, and HERCULES each show modest effect sizes; benefit is concentrated in patients with imaging or clinical inflammatory activity.
- BTK inhibitor class signal: mixed across HERCULES, GEMINI 1, GEMINI 2, and PERSEUS; positive in non-relapsing progressive disease, negative in relapsing disease, with hepatic safety considerations.
What the Evidence Does Not Show
Despite extensive randomised data, important questions in multiple sclerosis treatment remain unanswered. Each gap below identifies a specific clinical or methodological limit of current evidence rather than a generic call for more research.
⚠ Specific Knowledge Gaps
- No randomised trial has demonstrated long-term (10+ year) disability outcomes comparing anti-CD20 first-line use with traditional escalation strategies.
- Optimal de-escalation criteria — when, in whom, and to what — for patients in stable disease on high-efficacy therapy lack prospective trial guidance.
- Pregnancy and lactation safety data for ocrelizumab, ofatumumab, and BTK inhibitors derive primarily from registries rather than dedicated prospective studies.
- Tolebrutinib’s discordant phase 3 results across HERCULES versus GEMINI raise unresolved questions about which BTK-targeted populations will benefit and which will not.
- Direct head-to-head trials comparing anti-CD20 therapies, natalizumab, and S1P modulators on disability rather than relapse outcomes are limited.
- Real-world equity gaps in access to high-efficacy multiple sclerosis treatment — particularly in lower-income settings — are not addressed by efficacy trials.
Practical Implications for Multiple Sclerosis Treatment
Based on the current evidence, the following considerations support clinical decision-making in multiple sclerosis treatment. Each implication reflects what the trial data support rather than a directive recommendation.
Evidence Supports Discussing High-Efficacy First-Line Options
Brown 2019, He 2020, and emerging DELIVER-MS data support discussing high-efficacy disease-modifying therapy as a first-line option in newly diagnosed relapsing disease, particularly when poor prognostic features are present.
Anti-CD20 Therapy Shows Broad First-Line Suitability
OPERA and ASCLEPIOS data support ocrelizumab and ofatumumab as durable first-line options, with administration route and infection-monitoring profile guiding choice between them.
Progressive Disease Evidence Supports Early Action
ORATORIO, EXPAND, and HERCULES support initiating therapy when imaging or clinical inflammatory activity persists in progressive multiple sclerosis treatment, rather than withholding all disease-modifying therapy.
Pipeline Therapies Show Selective Benefit
Tolebrutinib evidence supports a potential future role specifically in non-relapsing secondary progressive disease, pending regulatory review and resolution of hepatic safety considerations.
Patient preference, comorbidity, family-planning considerations, and access to monitoring infrastructure should anchor any individual multiple sclerosis treatment plan. Trial evidence describes population-level effects; the consultation translates them into a strategy for one person.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong for relapse-rate efficacy; Moderate for sequencing strategy; Mixed for BTK inhibitor class. Multiple adequately powered randomised trials with concordant findings support anti-CD20 therapy efficacy and the modest benefit of ocrelizumab and siponimod in progressive disease. The high-efficacy first-line strategy is supported by consistent observational data and preliminary randomised signals, with definitive long-term disability outcomes still maturing.
Bottom Line
- Anti-CD20 monoclonal antibodies have set the modern efficacy benchmark in multiple sclerosis treatment, with consistent relapse-rate reductions across OPERA and ASCLEPIOS.
- Observational and emerging randomised evidence increasingly support early high-efficacy therapy over traditional escalation in newly diagnosed relapsing disease.
- Progressive multiple sclerosis treatment options remain limited; ocrelizumab, siponimod, and now tolebrutinib in non-relapsing secondary progressive disease offer modest benefit when inflammatory activity is present.
- BTK inhibitor evidence is mixed, with class effects appearing more relevant to compartmentalised inflammation than peripheral relapse biology.
- Long-term safety surveillance, de-escalation strategies, and equitable global access remain open questions in real-world multiple sclerosis treatment.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. DOI: 10.1056/NEJMoa1601277
- Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. DOI: 10.1056/NEJMoa1606468
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. DOI: 10.1056/NEJMoa1917246
- Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. DOI: 10.1056/NEJMoa044397
- Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828. DOI: 10.1016/S0140-6736(12)61769-3
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426. DOI: 10.1056/NEJMoa0902533
- Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. DOI: 10.1016/S0140-6736(18)30475-6
- Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321(2):175-187. DOI: 10.1001/jama.2018.20588
- He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. DOI: 10.1016/S1474-4422(20)30067-3
- Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025;392(13):1193-1204. DOI: 10.1056/NEJMoa2415988
- Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. DOI: 10.1038/s41572-018-0041-4
- Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. DOI: 10.1177/1352458520970841